Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis

First open IND for Abatas best-in-class autologous T cell receptor (TCR)-Treg cell therapy platform for autoimmune disease
Expected initiation of first-in-human Phase 1 study in patients by end of y… [+4321 chars]